Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses.


Journal

Journal of visualized experiments : JoVE
ISSN: 1940-087X
Titre abrégé: J Vis Exp
Pays: United States
ID NLM: 101313252

Informations de publication

Date de publication:
04 04 2019
Historique:
entrez: 23 4 2019
pubmed: 23 4 2019
medline: 19 3 2020
Statut: epublish

Résumé

The use of recombinant viruses has become crucial in basic or applied virology. Reverse genetics has been proven to be an extremely powerful technology, both to decipher viral replication mechanisms and to study antivirals or provide development platform for vaccines. The construction and manipulation of a reverse genetic system for a negative-strand RNA virus such as a respiratory syncytial virus (RSV), however, remains delicate and requires special know-how. The RSV genome is a single-strand, negative-sense RNA of about 15 kb that serves as a template for both viral RNA replication and transcription. Our reverse genetics system uses a cDNA copy of the human RSV long strain genome (HRSV). This cDNA, as well as cDNAs encoding viral proteins of the polymerase complex (L, P, N, and M2-1), are placed in individual expression vectors under T7 polymerase control sequences. The transfection of these elements in BSR-T7/5 cells, which stably express T7 polymerase, allows the cytoplasmic replication and transcription of the recombinant RSV, giving rise to genetically modified virions. A new RSV, which is present at the cell surface and in the culture supernatant of BSRT7/5, is gathered to infect human HEp-2 cells for viral amplification. Two or three rounds of amplification are needed to obtain viral stocks containing 1 x 10

Identifiants

pubmed: 31009004
doi: 10.3791/59218
doi:

Substances chimiques

DNA, Recombinant 0
Green Fluorescent Proteins 147336-22-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Camille Bouillier (C)

UMR 1173 Institut national de la santé et de la recherche médicale (INSERM), Université de Versailles St. Quentin.

Vincent Rincheval (V)

UMR 1173 Institut national de la santé et de la recherche médicale (INSERM), Université de Versailles St. Quentin.

Delphine Sitterlin (D)

UMR 1173 Institut national de la santé et de la recherche médicale (INSERM), Université de Versailles St. Quentin.

Sabine Blouquit-Laye (S)

UMR 1173 Institut national de la santé et de la recherche médicale (INSERM), Université de Versailles St. Quentin.

Aurore Desquesnes (A)

UMR 1173 Institut national de la santé et de la recherche médicale (INSERM), Université de Versailles St. Quentin.

Jean-François Eléouët (JF)

UR892 Institut national de la recherche agronomique (INRA), Unité de virologie et immunologie moléculaires.

Elyanne Gault (E)

UMR 1173 Institut national de la santé et de la recherche médicale (INSERM), Université de Versailles St. Quentin; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Ambroise Paré, Laboratoire de Microbiologie.

Marie-Anne Rameix-Welti (MA)

UMR 1173 Institut national de la santé et de la recherche médicale (INSERM), Université de Versailles St. Quentin; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Ambroise Paré, Laboratoire de Microbiologie; ma.welti@free.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH